This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.

Of the thousands of biomarkers that are currently being discovered, relatively few are being validated for further applications, and the potential of a biomarker can be quite difficult to evaluate. To aid in this imperative research, Dr. Kewal K. Jain’s Handbook of Biomarkers thoroughly describes many different types of biomarkers and their discovery using various "-omics" technologies, such as proteomics and metabolomics, along with the background information needed for the evaluation of biomarkers as well as the essential procedures for their validation and use in clinical trials. With biomarkers described first according to technologies and then according to various diseases, this detailed book features the key correlations between diseases and classifications of biomarkers, which provides the reader with a guide to sort out current and future biomarkers. Comprehensive and cutting-edge, The Handbook of Biomarkers serves as a vital guide to furthering our understanding of biomarkers, which, by facilitating the combination of therapeutics with diagnostics, promise to play an important role in the development of personalized medicine, one of the most important emerging trends in healthcare today.

This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists on the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.

"The field of Biomarkers and Precision Medicine in drug development is rapidly evolving and this book presents a snapshot of exciting new approaches. By presenting a wide range of biomarker applications, discussed by knowledgeable and experienced scientists, readers will develop an appreciation of the scope and breadth of biomarker knowledge and find examples that will help them in their own work." -Maria Freire, Foundation for the National Institutes of Health Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine. A wide variety of renowned experts from government, academia, teaching hospitals, biotechnology and pharmaceutical companies share best practices, examples and exciting new developments. The handbook aims to provide in-depth knowledge to research scientists, students and decision makers engaged in Biomarker and Precision Medicine-centric drug development. Features: Detailed insights into biomarker discovery, validation and diagnostic development with implementation strategies Lessons-learned from successful Precision Medicine case studies A variety of exciting and emerging biomarker technologies The next frontiers and future challenges of biomarkers in Precision Medicine Claudio Carini, Mark Fidock and Alain van Gool are internationally recognized as scientific leaders in Biomarkers and Precision Medicine. They have worked for decades in academia and pharmaceutical industry in EU, USA and Asia. Currently, Dr. Carini is Honorary Faculty at Kings’s College School of Medicine, London, UK. Dr. Fidock is Vice President of Precision Medicine Laboratories at AstraZeneca, Cambridge, UK. Prof.dr. van Gool is Head Translational Metabolic Laboratory at Radboud university medical school, Nijmegen, NL.

Principles of Tumors: A Translational Approach to Foundations, Second Edition, provides a concise summary of translational/interdisciplinary topics on the various aspects of tumors, especially abnormalities in their cells, their causes and effects on patients. Topics discussed include how genomic abnormalities in tumors may result from the actions of carcinogens and how genomic changes determine the cell biological/morphological abnormalities in tumor cell populations. In addition, the relationships between tumor cell genomics and therapeutic outcomes are described. There are also supporting appendices on general bioscience, including the principles of histology (the cells and tissues of the body), genetics, pathology, radiology and pharmacology. This book gives a thorough, detailed, yet concise account of the main bioscience, clinical and therapeutic aspects of tumors. It emphasizes the translational aspects of research into tumors with extensive discussions of interdisciplinary issues. The content in this book will be invaluable for researchers and clinicians involved in collaborative projects where it is necessary to understand fundamental issues in other branches of biomedicine. - Presents content that has been totally updated with the most recent developments of the field, including new chapters on tumor imaging exams, new surgical techniques, immunotherapy, gene therapy, and several novel therapies using natural and synthetic compounds - Presents translational approaches for every topic to improve conceptual insights for new research projects - Covers a broad range of subjects, making it easier for the reader to understand related fields - Includes diagrams for complex topics to aid in understanding for non-specialists

Handbook of Nano-biomaterials for Therapeutics and Diagnostic Applications covers in-depth topics on nano-biomaterials and nano drug delivery systems (biosensors and bioimaging) involving polymer nanocomposites, metal nanocomposites, and other carbon family fibers and proteins. The book covers the current application of tiny machines or nanodevices and their use as early detection systems for life threatening diseases, giving detailed literature on the development of nanodevices, their use as diagnostic tools, and their present trend in the industry and market. In addition, their synthesis, potential applications and future of smart nanodevices in diagnosis of diseases and their use as smart clinical devices is covered. Users will find sections on recent advances in interdisciplinary research on the processing, morphology, structure and properties of nanostructured materials and their applications in drug delivery for various diseases such as cancer, tuberculosis, Alzheimer disease, ophthalmic diseases, and more. - Offers a comprehensive coverage of the therapeutics and smart nanodevices as diagnostic tools and their potential clinical applications in biosensing and bioimaging - Includes a glimpse into the nano-biomaterials that are essential components in nanomedicines - Describes nanodevices in the early diagnosis of the diseases - Explains the nano-drug delivery system for the treatment of various diseases, including cancer, tuberculosis, Alzheimer disease, and ophthalmic diseases - Encompasses all information, starting from the design of nano-biomaterials to their applications in theranostics

With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today′s healthcare industry. The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace. The Handbook focuses on the aspects of paramount importance in the healthcare sector: - Pharmacoeconomics - Pharmacogenomics - Therapeutics - Diagnostics Areas covered include: - The role of nanotechnology, genomics and cell therapy in medicine - Diagnostics; Biomarkers and technological advances - Case studies in oncology and cardiovascular and CNS therapeutics

How to identify optimal phase II trial designs Providing a practical guide containing the information needed to make crucial decisions regarding phase II trial designs, A Practical Guide to Designing Phase II Trials in Oncology sets forth specific points for consideration between the statistician and clinician when designing a phase II trial, including issues such as how the treatment works, choice of outcome measure and randomization, and considering both academic and industry perspectives. A comprehensive and systematic library of available phase II trial designs is included, saving time otherwise spent considering multiple manuscripts, and real-life practical examples of using this approach to design phase II trials in cancer are given. A Practical Guide to Designing Phase II Trials in Oncology: Offers a structured and practical approach to phase II trial design Considers trial design from both an academic and industry perspective Includes a structured library of available phase II trial designs Is relevant to both clinical and statistical researchers at all levels Includes real life examples of applying this approach For those new to trial design, A Practical Guide to Designing Phase II Trials in Oncology will be a unique and practical learning tool, providing an introduction to the concepts behind informed decision making in phase II trials. For more experienced practitioners, the book will offer an overview of new, less familiar approaches to phase II trial design, providing alternative options to those which they may have previously used.

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever and whenever you need it most! Equips you to select the most appropriate tests and imaging studies for diagnosing and staging each type of cancer, and manage your patients most effectively using all of the latest techniques and approaches. Explores all of the latest scientific discoveries' implications for cancer diagnosis and management. Employs a multidisciplinary approach - with contributions from pathologists, radiation oncologists, medical oncologists, and surgical oncologists - for well-rounded perspectives on the problems you face. Offers a user-friendly layout with a consistent chapter format • summary boxes • a full-color design • and more than 1,445 illustrations (1,200 in full color), to make reference easy and efficient. Offers access to the book's complete contents online – fully searchable – from anyplace with an Internet connection. Presents discussions on cutting-edge new topics including nanotechnology, functional imaging, signal transduction inhibitors, hormone modulators, complications of transplantation, and much more. Includes an expanded color art program that highlights key points, illustrates relevant science and clinical problems, and enhances your understanding of complex concepts.

The past decade has been marked by the acceleration of our understanding of the molecular biology of cancer. Simultaneously, there have been increasing exigencies to diagnose, treat and follow cancer patients more economically. Biomarkers represent the marriage of science and economics. Biomarkers offer the potential to increase the precision of diagnosis, prognosis, and surveillance of urological malignancies. This issue presents the cutting-edge advances of biomarker technology to urologic oncology.